Immune Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Immune Therapeutics generated cash of -$581,821, which is less than the previous year. Cash used in financing activities reached the amount of $738,427 last year. Net change in cash is therefore -$343,394.
Cash Flow
| 2013 | -6.57M | -166.37K | 6.83M |
|---|---|---|---|
| 2014 | -3.84M | -58.45K | 3.68M |
| 2015 | -2.83M | 0 | 2.66M |
| 2016 | -2.83M | -1.72K | 2.89M |
| 2017 | -2.05M | -1.50K | 1.99M |
| 2018 | -1.36M | -1.97K | 1.36M |
| 2019 | -934 | 0 | 0 |
| 2020 | -191.95K | 0 | 197K |
| 2021 | -231.71K | 0 | 715.63K |
| 2022 | -581.82K | -500K | 738.42K |
IMUN Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 493.88K | 9.97K | 4.92K | 5.85K | 14.71K | 74.38K | 23.14K | 191.98K | 406.59K | 313.09K |
Operating activities | ||||||||||
Net income | -3.53M | 3.58M | 1.58M | -3.39M | -8.62M | -7.93M | -19.81M | -16.94M | -49.93M | -106.06M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 639 | 2.07K | 1.73K | 826 | 1.55K | 594.78K | 2.87M | 2.85M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 13.53K | -16.19K | 0 | 0 |
Inventories | 0 | 0 | 0 | 82.80K | 95.29K | -178.09K | 0 | 0 | 0 | 0 |
Accounts payable | 388.53K | 103.75K | 99.23K | 894.95K | 341.56K | 919.14K | 540.98K | 900.48K | 1.79M | 553.21K |
Cash generated by operating activities | -581.82K | -231.71K | -191.95K | -934 | -1.36M | -2.05M | -2.83M | -2.83M | -3.84M | -6.57M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -500K | 0 | 0 | 0 | -1.97K | -1.50K | -1.72K | 0 | -58.45K | -166.37K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -500K | 0 | 0 | 0 | -1.97K | -1.50K | -1.72K | 0 | -58.45K | -166.37K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 240.5K | 706.53K | 200K | 605.5K | 2.23M | 6.55M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -75.92K | 0 | -50K | -100K |
Cash used in financing activities | 738.42K | 715.63K | 197K | 0 | 1.36M | 1.99M | 2.89M | 2.66M | 3.68M | 6.83M |
Net Change In Cash | -343.39K | 483.91K | 5.04K | -934 | -8.85K | -59.67K | 51.24K | -168.83K | -214.60K | 93.50K |
Cash at end of period | 150.49K | 493.88K | 9.97K | 4.92K | 5.85K | 14.71K | 74.38K | 23.14K | 191.98K | 406.59K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |